These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 33741729)

  • 1. Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche.
    Müller LME; Migneco G; Scott GB; Down J; King S; Askar B; Jennings V; Oyajobi B; Scott K; West E; Ralph C; Samson A; Ilett EJ; Muthana M; Coffey M; Melcher A; Parrish C; Cook G; Lawson M; Errington-Mais F
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
    Gebremeskel S; Nelson A; Walker B; Oliphant T; Lobert L; Mahoney D; Johnston B
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus.
    Prestwich RJ; Errington F; Steele LP; Ilett EJ; Morgan RS; Harrington KJ; Pandha HS; Selby PJ; Vile RG; Melcher AA
    J Immunol; 2009 Oct; 183(7):4312-21. PubMed ID: 19734207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21.
    Müller LME; Holmes M; Michael JL; Scott GB; West EJ; Scott KJ; Parrish C; Hall K; Stäble S; Jennings VA; Cullen M; McConnell S; Langton C; Tidswell EL; Shafren D; Samson A; Harrington KJ; Pandha H; Ralph C; Kelly RJ; Cook G; Melcher AA; Errington-Mais F
    J Immunother Cancer; 2019 Jul; 7(1):164. PubMed ID: 31262361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reovirus as a viable therapeutic option for the treatment of multiple myeloma.
    Thirukkumaran CM; Shi ZQ; Luider J; Kopciuk K; Gao H; Bahlis N; Neri P; Pho M; Stewart D; Mansoor A; Morris DG
    Clin Cancer Res; 2012 Sep; 18(18):4962-72. PubMed ID: 22761466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma.
    Lawson KA; Mostafa AA; Shi ZQ; Spurrell J; Chen W; Kawakami J; Gratton K; Thakur S; Morris DG
    Clin Cancer Res; 2016 Dec; 22(23):5839-5850. PubMed ID: 27220962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication.
    Prestwich RJ; Ilett EJ; Errington F; Diaz RM; Steele LP; Kottke T; Thompson J; Galivo F; Harrington KJ; Pandha HS; Selby PJ; Vile RG; Melcher AA
    Clin Cancer Res; 2009 Jul; 15(13):4374-4381. PubMed ID: 19509134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity.
    Ilett EJ; Prestwich RJ; Kottke T; Errington F; Thompson JM; Harrington KJ; Pandha HS; Coffey M; Selby PJ; Vile RG; Melcher AA
    Gene Ther; 2009 May; 16(5):689-99. PubMed ID: 19282847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Myeloid Cells in Oncolytic Reovirus-Based Cancer Therapy.
    Kumar V; Giacomantonio MA; Gujar S
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33920168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small extracellular vesicles carrying reovirus, tumor antigens, interferon-β, and damage-associated molecular patterns for efficient tumor treatment.
    Shuwari N; Inoue C; Ishigami I; Jingushi K; Kamiya M; Kawakami S; Tsujikawa K; Tachibana M; Mizuguchi H; Sakurai F
    J Control Release; 2024 Oct; 374():89-102. PubMed ID: 39122217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune priming.
    Steele L; Errington F; Prestwich R; Ilett E; Harrington K; Pandha H; Coffey M; Selby P; Vile R; Melcher A
    Mol Cancer; 2011 Feb; 10():20. PubMed ID: 21338484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytotoxic and immune-mediated killing of human colorectal cancer by reovirus-loaded blood and liver mononuclear cells.
    Adair RA; Scott KJ; Fraser S; Errington-Mais F; Pandha H; Coffey M; Selby P; Cook GP; Vile R; Harrington KJ; Toogood G; Melcher AA
    Int J Cancer; 2013 May; 132(10):2327-38. PubMed ID: 23114986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor infection by oncolytic reovirus primes adaptive antitumor immunity.
    Prestwich RJ; Errington F; Ilett EJ; Morgan RS; Scott KJ; Kottke T; Thompson J; Morrison EE; Harrington KJ; Pandha HS; Selby PJ; Vile RG; Melcher AA
    Clin Cancer Res; 2008 Nov; 14(22):7358-66. PubMed ID: 19010851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy.
    Ilett E; Kottke T; Thompson J; Rajani K; Zaidi S; Evgin L; Coffey M; Ralph C; Diaz R; Pandha H; Harrington K; Selby P; Bram R; Melcher A; Vile R
    Gene Ther; 2017 Jan; 24(1):21-30. PubMed ID: 27779616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reovirus activates human dendritic cells to promote innate antitumor immunity.
    Errington F; Steele L; Prestwich R; Harrington KJ; Pandha HS; Vidal L; de Bono J; Selby P; Coffey M; Vile R; Melcher A
    J Immunol; 2008 May; 180(9):6018-26. PubMed ID: 18424722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphokine-activated killer and dendritic cell carriage enhances oncolytic reovirus therapy for ovarian cancer by overcoming antibody neutralization in ascites.
    Jennings VA; Ilett EJ; Scott KJ; West EJ; Vile R; Pandha H; Harrington K; Young A; Hall GD; Coffey M; Selby P; Errington-Mais F; Melcher AA
    Int J Cancer; 2014 Mar; 134(5):1091-101. PubMed ID: 23982804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia.
    Parrish C; Scott GB; Migneco G; Scott KJ; Steele LP; Ilett E; West EJ; Hall K; Selby PJ; Buchanan D; Varghese A; Cragg MS; Coffey M; Hillmen P; Melcher AA; Errington-Mais F
    Leukemia; 2015 Sep; 29(9):1799-810. PubMed ID: 25814029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
    Podar K; Jager D
    Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transplantation of autologous bone marrow pre-loaded
    Villa NY; Rahman MM; Mamola J; Sharik ME; de Matos AL; Kilbourne J; Lowe K; Daggett-Vondras J; D'Isabella J; Goras E; Chesi M; Bergsagel PL; McFadden G
    Oncotarget; 2022; 13():490-504. PubMed ID: 35251496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy.
    Groeneveldt C; Kinderman P; van Stigt Thans JJC; Labrie C; Griffioen L; Sluijter M; van den Wollenberg DJM; Hoeben RC; den Haan JMM; van der Burg SH; van Hall T; van Montfoort N
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35853671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.